巨生生醫股份有限公司 MegaPro Biomedical Co., Ltd.
Climate Impact & Sustainability Data (2021)
Reporting Period: 2021
Environmental Metrics
ESG Focus Areas
- Governance
- Environmental
- Social
Environmental Achievements
- adopted energy-saving lighting, implemented waste reduction and recycling programs, and promoted reduced waste generation.
- The company's operations are primarily office-based, resulting in minimal environmental impact. Efforts are made to reduce energy and water consumption.
Social Achievements
- Regular labor-management meetings are held, with employee representatives from each department participating. Employee benefits include labor insurance, retirement funds, national health insurance, and company-sponsored welfare programs.
- The company provides a safe and healthy work environment, offers health check subsidies, and conducts workplace safety training.
Governance Achievements
- In 2021, the company held a shareholder's meeting to completely replace its board of directors and independent directors, establishing an audit committee to replace the supervisory board.
- A remuneration committee was established in February 2021 to ensure transparency and fair compensation for directors and managers.
Climate Goals & Targets
Medium-term Goals:
- Develop new product lines based on the company's nanotechnology platforms.
Short-term Goals:
- Complete international licensing of MPB-1514 and MPB-1523, and complete Phase 3 clinical trials and obtain drug approvals.
- Advance enrollment in the MPB-1734 Phase 1/2a clinical trial.
Environmental Challenges
- Delays in clinical trials for MPB-1734 due to the COVID-19 pandemic.
- The high cost and lengthy duration of clinical trials.
Mitigation Strategies
- Collaborating with domestic and international pharmaceutical companies to accelerate product launches and share clinical trial results.
- Exploring various partnerships to reduce the financial burden and risk of clinical trials.
- Diversifying product portfolio to increase the likelihood of successful drug development.